Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended September 30, 1999, for Advanced Polymer Systems, Inc. (APS). The registrant develops and sells Microsponge and Polytrap delivery systems for personal care, cosmetic, and pharmaceutical applications. The financial statements for the current and prior periods have been restated to reflect a change in accounting policy regarding the amortization of license fees over the estimated life of the related product.
Key Financial Metrics
| Metric | Three Months Ended Sept 30, 1999 | Nine Months Ended Sept 30, 1999 |
|---|---|---|
| Total Revenues | $5,181,135 | $14,915,660 |
| Net Income | $610,071 | $1,652,677 |
| Earnings Per Share (Diluted) | $0.03 | $0.08 |
| Cash and Cash Equivalents | $3,152,576 (Sept 30, 1999) | N/A |
| Working Capital | $8,857,513 (Sept 30, 1999) | N/A |
| Total Debt (Current + Long-term) | $3,516,292 (Sept 30, 1999) | N/A |
| Net Cash Used in Operating Activities | N/A | $(1,525,864) |
Material Changes vs. Prior Period
- Revenue Growth: Total revenues increased 4% ($196,000) for the three months ended September 30, 1999, compared to the restated prior year period. Product revenues rose 14% driven by a 50% increase in sales of Microsponge-entrapped retinol and Vitamin K formulations, partially offset by a 32% decline in toiletries sales due to the discontinuation of a baby-wipe product.
- Profitability: Net income for the three months ended September 30, 1999, was $610,071, compared to $354,662 in the prior year. Gross profit margin on product revenues improved to 52% due to a favorable sales mix shift toward higher-margin cosmeceutical products.
- Expense Management: Selling and marketing expenses decreased 8% quarter-over-quarter due to reduced headcount. General and administrative expenses increased 7% primarily due to higher director and professional fees related to a resolved proxy contest.
- Debt Refinancing: In March 1999, the company secured a $4,000,000 term loan at 13.87% interest to refinance scheduled debt payments. This resulted in a decrease in interest expense of 22% for the quarter compared to the prior year.
- Restatement Impact: Prior period results were restated to amortize license fees over the product life rather than recognizing them immediately. This reduced reported revenues and net income for the comparable 1998 periods.
Guidance, Outlook, and Risks
- Liquidity Outlook: Management expects existing cash, receivables, and revenue streams to be sufficient to meet working capital requirements for the foreseeable future.
- Year 2000 (Y2K) Contingency: The company has incurred approximately $600,000 to remediate systems and built up inventory by approximately $1,000,000 as a contingency plan. While internal systems are compliant, risks remain regarding third-party suppliers and customers failing to remediate their systems.
- Legal Settlement: A $1,300,000 settlement with Biosource Technologies, Inc. was fully paid in 1999 ($300,000 in January and $1,000,000 in May), terminating the license and supply agreement between the parties.
- Related Party Transactions: As of September 30, 1999, the company holds a $276,000 secured loan receivable from an officer, due by December 31, 1999.
Investor Verification Checklist
- Restatement Details: Verify the specific impact of the accounting change on license fee recognition (Note 11) and ensure comparability with historical data.
- Debt Covenants: Review the terms of the $4,000,000 term loan secured by manufacturing assets and receivables to understand repayment obligations and potential refinancing risks.
- Y2K Exposure: Assess the company's reliance on third-party vendors and the adequacy of the $1,000,000 inventory buffer against potential supply chain disruptions.
- Revenue Concentration: Analyze the dependency on specific high-margin cosmeceutical launches versus the decline in traditional toiletries sales.
- Related Party Loan: Confirm the repayment status of the $276,000 officer loan receivable as of the period end.